Episode Details

Today, we’re joined by Dipal Doshi, a leader at theforefront of modern biotechnology and rare disease innovation. As CEO of Entrada Therapeutics, Dipal has helped build the company from its earliest days into a clinical-stage pioneer focused on unlocking intracellular therapies.

With a career that spans investment banking at MerrillLynch, global pharma at Eli Lilly and Company, and senior leadership roles at Amicus Therapeutics, Dipal brings a unique blend of financial, strategic, and commercial expertise to the biotech world.

Now Dipal's leading Entrada Therapeutics, who are aclinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, they are advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others.